Reply to Comments: “Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis” Int. J. Mol. Sci., 2019, 20, 4986

Dear Editor,

In Dr. Magdalena Szaryńska’s recent letter, she expressed one confusing aspect she met in Figure 1 [1]. We had already corrected and published on [2], circulating thyroid hormones (THs) interact with thyroid hormone receptors to promote downstream signaling pathways and activate transcription factors. Thyroid hormone receptors (TR) including TRα and TRβ contain several domains; specifically, these are the amino-terminal A/B that may function as a gene enhancer, the DNA-binding domain (DBD), the hinge region containing the nuclear localization signal and the carboxy-terminal ligand-binding domain (LBD) that binds T3 through AF-2, which is a surface-exposed hydrophobic included residue from H3 and H5 and is completed by T3-dependent packing of C-terminal H12 against the LBD which affects target genes transcription [3,4]. (Figure 1). The four major TR isoforms, TRα1, TRα2, TRβ1, and TRβ2, are produced by c-erbAα and c-erbAβ genes. Their human homologs are designated THRA and THRB. The c-erbAα gene located on chromosome 17 encodes two different TRα isoforms. One is functional TH-binding TRα1 and the other is a dominant-negative splice variant, TRα2, lacking TH binding activity [5]. T3 interacts with thyroid hormone receptors via C-terminal activation function-2 (AF-2) in the ligand-binding domain (LBD), however, only TRα2 has a distinct C-terminal extension and is absent the activation function-2 (AF-2) region, which suggested that TRα2 does not bind T3 [6]. TRα2 is unique in consideration of its lack of binding to THs while interacting with DNA, and its precise function is unclear at present. We have corrected to show that the TRα2 didn’t bind T3 and have marked the presence or absence of the AF-2 domain in Figure 1 as follows: